Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Caputo

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseFortunato Ciardiello, Rosa Caputo, Vincenzo Damiano, et al.
International Journal of Molecular Sciences|September 9, 2020
Targeting Cell Cycle in Breast Cancer: CDK4/6 InhibitorsMichela Piezzo, Stefania Cocco, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapyFortunato Ciardiello, Roberto Bianco, Roberta Caputo, et al.
International Journal of Molecular Sciences|October 27, 2020
Targeting Autophagy in Breast CancerStefania Cocco, Alessandra Leone, Michela Piezzo, et al.
Journal of Translational Medicine|June 27, 2022
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer modelsStefania Cocco, Alessandra Leone, Maria Serena Roca, et al.
Scientific Reports|May 9, 2025
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regionsRaffaele Ardito, Grazia Arpino, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)Cataldo Bianco, Giampaolo Tortora, Roberto Bianco, et al.
Eclinicalmedicine|August 9, 2023
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsAndrea D'Arienzo, Annarita Verrazzo, Martina Pagliuca, et al.
Frontiers in Oncology|April 10, 2024
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysisRoberta Caputo, Giuseppe Buono, Michela Piezzo, et al.
Future Oncology (London, England)|August 22, 2023
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinionRoberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinaseFortunato Ciardiello, Rosa Caputo, Vincenzo Damiano, et al.
International Journal of Molecular Sciences|September 9, 2020
Targeting Cell Cycle in Breast Cancer: CDK4/6 InhibitorsMichela Piezzo, Stefania Cocco, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapyFortunato Ciardiello, Roberto Bianco, Roberta Caputo, et al.
International Journal of Molecular Sciences|October 27, 2020
Targeting Autophagy in Breast CancerStefania Cocco, Alessandra Leone, Michela Piezzo, et al.
Journal of Translational Medicine|June 27, 2022
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer modelsStefania Cocco, Alessandra Leone, Maria Serena Roca, et al.
Scientific Reports|May 9, 2025
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regionsRaffaele Ardito, Grazia Arpino, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)Cataldo Bianco, Giampaolo Tortora, Roberto Bianco, et al.
Eclinicalmedicine|August 9, 2023
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsAndrea D'Arienzo, Annarita Verrazzo, Martina Pagliuca, et al.
Frontiers in Oncology|April 10, 2024
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysisRoberta Caputo, Giuseppe Buono, Michela Piezzo, et al.
Future Oncology (London, England)|August 22, 2023
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinionRoberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, et al.
Pageof 5